FIELD: chemistry.SUBSTANCE: invention relates to field of organic chemistry, namely to novel imidazole derivative of general formula, or to its pharmacologically acceptable salt, where A represents group:, where * represents position for substitution； R, Rand R, each represents hydrogen atom； Rrepresents hydrogen atom or prodrug group； and Y represents group: -CH-CHR-CH-NHR(where Rrepresents hydrogen atom or C1-C6alkyl group, and Rrepresents hydrogen atom or prodrug group), -O-CHR-CH-NHR(where Rrepresents hydrogen atom C1-C6alkyl group, and Rrepresents hydrogen atom) or, (where Rrepresents hydrogen atom, and * represents position for substitution)； where prodrug group, represented by R, represents [(isopropoxycarbonyl)oxy]ethyl group or C1-C6alkyl group, which is substituted with one phenyl group； and where prodrug group, represented by R, represents C1-C6alkanoyl group, which is substituted with one or two similar or different groups, selected from aminogroup and phenyl group； (C1-C6alcoxy)carbonyl group； substituted with one group, selected from C2-C6alkanoyloxy group and (C3-C6cycloalkyl)carbonyloxy group； or 1,3-dioxol-methoxycarbonyl group, substituted with two different groups, selected from oxogroup and C1-C6alkyl group. Invention also relates to particular compounds and salts, TAFIa inhibitor, fibrinolysis promoter, pharmaceutical composition and preventive or therapeutic medication based on formula (I) compound, as well as to intermediate compounds of formulae,and.EFFECT: novel imidazole derivatives, possessing TAFIa-inhibiting activity have been obtained.59 cl, 4 dwg, 4 tbl, 50 exИзобретение относится к области органической химии, а именно к новому производному имидазола общей формулы (I), или к его фармакологически приемлемой соли, где А представляет собой группу:, где * представляет собой положение для замещения； R, Rи R, каждый представляет собой атом водорода； Rпредставляет собой атом водорода или группу пролекарства； и Y представляет собой группу: -CH
